|
|
| Product Name: | BC2059 | | Synonyms: | BC2059;BC-2059;BC2059;TEGAVIVINT;Tegavivint;TEGATRABETAN;BC-2059;TEGAVIVINT;9,10-Anthracenedione, 2,7-bis[[(3R,5S)-3,5-dimethyl-1-piperidinyl]sulfonyl]-, 9,10-dioxime, rel-;rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime;Tegatrabetan (BC2059);Tegatrabetan,inhibit,Inhibitor,β-catenin,BC-2059,Beta catenin,BC 2059 | | CAS: | 1227637-23-1 | | MF: | C28H36N4O6S2 | | MW: | 588.74 | | EINECS: | | | Product Categories: | | | Mol File: | 1227637-23-1.mol |  |
| | BC2059 Chemical Properties |
| Boiling point | 757.6±70.0 °C(Predicted) | | density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO: 125 mg/mL (212.32 mM) | | pka | 10.07±0.20(Predicted) |
| | BC2059 Usage And Synthesis |
| Biological Activity | Tegatrabetan (BC2059) is a beta-Catenin antagonist. It disrupts β-catenin binding to scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and reduces β-catenin nuclear levels. | | in vivo | Tegatrabetan (BC2059; 1.0 or 5.0 mg/kg/day; intravenously) significantly improves the median survival of the mice from approximately 17.5 to 39 days. Treatment with Tegatrabetan (10 mg/kg/day; intravenously) alone further improves the median survival to 51.5 days. | Animal Model: | NOD/SCID mice bearing OCI-AML3 xenografts | < /tr> | Dosage: | 1 mg/kg; 5 mg/kg; 10 mg/kg | | Administration: | Intravenously; 1 mg/kg daily 4 days per week or 5 mg/kg or 10 mg/kg of BC2059 twice per week (Tuesday and Thursday) for 3 weeks. | | Result: | Treatment significantly improved survival of NOD/SCID mice bearing OCI-AML3 xenografts. | | | target | |
| | BC2059 Preparation Products And Raw materials |
|